These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39236453)

  • 1. Clinical outcome and prognostic factors for immunotherapy-based treatments in patients with platinum-refractory germ cell tumor.
    Huang R; Shu D; Li H; Hu A; Chen M; Yang W; Zhang Y; Zheng Q; An X; Xue C; Shi Y
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113042. PubMed ID: 39236453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor.
    Takada A; Ii N; Hirayama M; Toyoda H; Matsubara T; Toyomasu Y; Kawamura T; Daimon T; Sakuma H; Nomoto Y
    J Neurosurg Pediatr; 2019 Mar; 23(3):317-324. PubMed ID: 30497152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
    Semaan A; Haddad FG; Eid R; Kourie HR; Nemr E
    Future Oncol; 2019 Feb; 15(5):533-541. PubMed ID: 30624089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
    Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
    Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
    Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
    Massard C; Kramar A; Beyer J; Hartmann JT; Lorch A; Pico JL; Rosti G; Droz JP; Fizazi K
    Ann Oncol; 2013 Feb; 24(2):322-328. PubMed ID: 23104726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology.
    Takami H; Graffeo CS; Perry A; Giannini C; Nakazato Y; Saito N; Matsutani M; Nishikawa R; Daniels DJ; Ichimura K
    Brain Tumor Pathol; 2023 Apr; 40(2):124-132. PubMed ID: 36995447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
    Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
    Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
    Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
    J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience.
    Yildiran Keskin GS; Erturk I; Aykan MB; Acar R; Dumludag A; Topal A; Koseoglu C; Kuzu OF; Ornek E; Karadurmus N
    Oncol Res Treat; 2024; 47(6):262-272. PubMed ID: 38583428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors.
    Kawaguchi T; Kumabe T; Kanamori M; Saito R; Yamashita Y; Sonoda Y; Watanabe M; Tominaga T
    J Neurooncol; 2011 Sep; 104(3):779-87. PubMed ID: 21359564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
    Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
    J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
    Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
    Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
    Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors.
    Kim A; Ji L; Balmaceda C; Diez B; Kellie SJ; Dunkel IJ; Gardner SL; Sposto R; Finlay JL
    Pediatr Blood Cancer; 2008 Dec; 51(6):768-73. PubMed ID: 18802946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphologic features of human chorionic gonadotropin- or alpha-fetoprotein-producing germ cell tumors of the central nervous system: histological heterogeneity and surgical meaning.
    Sugiyama K; Arita K; Tominaga A; Hanaya R; Taniguchi E; Okamura T; Itoh Y; Yamasaki F; Kurisu K
    Brain Tumor Pathol; 2001; 18(2):115-22. PubMed ID: 11908867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
    Stevens MJ; Norman AR; Dearnaley DP; Horwich A
    J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Childhood ovarian nonseminomatous germ cell tumors: A highly curable disease with few long-term treatment-related toxicities-Results of the French TGM95 study.
    Pavone R; Pacquement H; Pasquet M; Sudour-Bonnange H; Hameury F; Sarnacki S; Chastagner P; Faure-Conter C; Poirée M; Taque S; Patte C; Fresneau B
    Int J Cancer; 2021 Nov; 149(9):1705-1712. PubMed ID: 34146403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.